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DEAR EDITOR, The prevalence of spondyloarthritis (SpA)
reported among patients with hidradenitis suppurativa (HS)
ranges from 23% to 282%, depending on the diagnostic
method used.1 A key feature of SpA and one of the European
Spondyloarthropathy Study Group diagnostic criteria for this
group of diseases is enthesitis: inflammation at the insertion
of tendons, ligaments and capsules. However, pain at an
entheseal site is nonspecific and does not always indicate
inflammation. Objective assessment of the presence of enthesi-
tis can be done using ultrasound.2 Therefore, the aim of this
cross-sectional study was to investigate the prevalence of clini-
cal enthesitis among patients with HS and to correlate it with
sonographic enthesitis.
Patients were selected randomly prior to their routine visit
at the specialized HS outpatient clinic of a tertiary centre in
the Netherlands between October 2018 and February 2019.
The study was approved by the medical ethical committee of
the Erasmus University Medical Center (MEC-2018-158).
Patient characteristics were collected through the HiScreen
Registry (MEC-2016-426) and patient charts.
Clinical enthesitis, defined as pain elicited by local pressure
at the enthesis, was assessed bilaterally at eight entheseal
points (total 16 sites) according to the Spondyloarthritis
Research Consortium of Canada (SPARCC) criteria.3 Ultra-
sound examination was performed according to the Madrid
Sonographic Enthesitis Index at six bilateral entheses and sono-
graphic enthesitis was defined according to the Outcome Mea-
sures in Rheumatology criteria.4
In total, 100 patients were included; see Table 1 for patient
characteristics. Eighteen patients had visited a rheumatologist
previously, five of whom were diagnosed with SpA, one with
rheumatoid arthritis and one with sarcoidosis. Eleven patients
were seen for nonrheumatic pain complaints, three of whom
were diagnosed with fibromyalgia. On clinical examination,
53% of patients could be diagnosed with clinical signs of
enthesitis in at least one enthesis. The number of painful
entheses in these patients ranged from one to 14 per individ-
ual; 585% had four or more affected entheses, and seven
patients had an enthesitis count of over 10. Sonographic
enthesitis was seen in 25% of patients. Assessing the entheses
that were evaluated both clinically and sonographically
showed that 132% of clinically painful entheses had an
underlying sonographic enthesitis. Neither clinical nor sono-
graphic enthesitis was associated with Hurley stage or the
International Hidradenitis Suppurativa Severity Score System
(IHS4) score.
In summary, this is the first cross-sectional study in patients
with HS in which clinical assessment of enthesitis was objecti-
fied by ultrasound. The 25% prevalence of sonographic enthe-
sitis in our study is slightly higher than the 20% prevalence
found in patients with psoriasis.5
Table 1 Patient characteristics
N = 100
Sex
Female, n (%) 80 (80)
Age, mean (SD) 390 (110)
Age of onset, median (IQR) 180 (140–290)
Missing, n 3
Body mass index, mean (SD) 298 (60)
Missing, n 14
Smoking status
Current or former smoker, n (%) 70 (753)
Never smoked, n (%) 23 (247)
Missing, n 7
Family history of HS
Positive in 1st of 2nd degree, n (%) 32 (333)
Negative, n (%) 55 (573)
Unknown, n (%) 9 (94)
Missing, n 4
Comorbidities
Rheumatological comorbidities, n (%) 8 (81)
Missing, n 1
Inflammatory bowel disease, n (%) 5 (51)
Missing, n 2
Family history of SpA, n (%) 12 (120)
Missing, n 0
Hurley stage
I, n (%) 47 (475)
II, n (%) 44 (444)
III, n (%) 8 (81)
Missing, n 1
IHS4, mean (SD) 43 (07)
Current use of anti-TNF-a biologics, n (%) 6 (61)
Missing, n 1
Use of pain medication, n (%) 36 (36)
Use of opioids, n (%) 6 (6)
HS, hidradenitis suppurativa; IHS4, International Hidradenitis
Suppurativa Severity Score System; IQR, interquartile range; SpA,
spondyloarthritis; TNF, tumour necrosis factor
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The prevalence of clinical enthesitis (53%) was over twice
that of sonographic enthesitis in our HS population, and many
painful entheses could not be explained by underlying sono-
graphic abnormalities. This high rate could be a consequence
of the unspecific nature of entheseal tenderness, which is fur-
ther supported by the high percentage of patients that had
over four affected entheses.
A study on patients with psoriasis, psoriatic arthritis and
fibromyalgia showed that the frequency of entheseal tender-
ness was higher in patients with fibromyalgia than in patients
with psoriatic arthritis or psoriasis: respectively, 92% vs. 66%
and 59%.6 Moreover, the number of affected entheses was
higher in the fibromyalgia group (46%) than in the psoriatic
arthritis (23%) or psoriasis (18%) groups.6 This raises the
question of whether the chronic, widespread musculoskeletal
pain associated with HS could in part be due to other causes.
Tenderness at entheseal sites has an overlap with the tender
points originally used for the diagnosis of fibromyalgia
according to the American College of Rheumatology (ACR)-
1990 criteria (changed to pain sites in the ACR-2010/2011
and ACR-2016 criteria). The underlying rationale is similar
and studies have shown that clinical differentiation between
fibromyalgia and enthesitis can be extremely challenging.7
Our study could have been influenced by inclusion bias as
patients who experience joint complaints could be more
inclined to participate. Moreover, observer expectancy bias
could have influenced our results as both clinical and ultra-
sound examination were performed by the same investigator.
In addition, it is known that age and body mass index (BMI)
are positively correlated with the presence of enthesitis in the
lower limbs.8 Therefore, the high BMI and age in our popula-
tion could have influenced the prevalence of enthesitis. Yet
this does not explain the discrepancy between clinical and
sonographic enthesitis.
In conclusion, the high number of clinically painful enthe-
ses could be explained only in part by underlying sonographic
enthesitis. This finding, in combination with the high propor-
tion of patients with more than four clinical enthesitis sites,
suggests that different pathologies might explain the wide-
spread (entheseal) pain among patients with HS and requires
further investigation as treatment differs for the different
causes. Therefore, we urge dermatologists to refer patients
with HS with musculoskeletal complaints to a rheumatologist
to identify the underlying cause.
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